Chemotherapy Research / Regimen
Chemotherapy No Comments »Quick post – I talked to my medical oncologist and we are reconsidering our approach with the pulse therapy. I mentioned in my previous post that we were moving forward with Temodar – 5 days on per month and the remainder of each month I would be off the medication. There is some research that has been uncovered that indicates that patient’s survival rates have increased by being on a daily dose of Temodar indefinitely (at least through 6 month checkpoints to see status) as opposed to the current standard of care which is the 5-day pulse therapy. There was a study done in Europe that involved patients with high-grade gliomas. These patients had glioblastoma multiforme tumors. Of these patients, half were given the 5-day pulse therapy and half were given the daily dose. Those given a daily dose instead of the 5-day pulse increased their survival rate two-fold.
The sample was small – it involved only 100 or so patients. However, the results speak for themselves and when you are dealing with what I am dealing with, you will try certain things regardless – within reason. I am in the process of switching things up. The trade-off of course is quality of life but I handled the daily dose ok before. The concern will be long-term. My white cell count may dip pretty low. WBC is what helps your body fight infection. My red cell count may also fall – red blood cells carry oxygen and nutrients to all areas of the body. The other concern is platelets. Platelets help blood to clot. They are found in the blood flowing through your blood vessels. Platelets also line the inside of the blood vessels. When low blood platelet count is present, this layer thins and tiny drops of blood can leak through the spaces made when this layer thins, causing red dots on the skin called petechiae which leads to increase bruising, bleeding from the nose, gums, etc. The gist of all of it is that everything needs to be managed but certainly these are not risks that are reason enough to not do it! Double the survival rate, at least based on this small study? You have to move forward.
I haven’t seen this research before and I’ve dug a lot of holes and searched high and low. This is new and obviously oncologists have access to research banks that we just do not. I’m very grateful I have an oncologist that is on top of this and doesn’t just move forward with the “standard of care” and floats these types of approaches in front of me.
Site Search Tags: glioma, chemotherapy, tumor, onlocology, temodar, gbm







